By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
AdkhabarAdkhabarAdkhabar
Notification Show More
Font ResizerAa
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Reading: IPSEN – Buy-back programme – Art 5 of MAR – Week 36 – 2025
Share
Font ResizerAa
AdkhabarAdkhabar
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Search
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Follow US
Adkhabar > Blog > Health > IPSEN – Buy-back programme – Art 5 of MAR – Week 36 – 2025
IPSEN – Buy-back programme – Art 5 of MAR – Week 36 – 2025
Health

IPSEN – Buy-back programme – Art 5 of MAR – Week 36 – 2025

GlobeNews Wire
Last updated: 09/09/2025 11:36 PM
GlobeNews Wire
Published: 09/09/2025
Share
SHARE
Aggregated presentation by day and by market

Statement of transactions in own shares from 1st September to 5th September 2025

             
Name of the issue Identity code of the issuer
(Legal Entity Identifier)
Day of the transaction Identity code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market         (MIC Code)
  IPSEN 549300M6SGDPB4Z94P11 01/09/2025 FR0010259150    632 116,87753 AQEU  
  IPSEN 549300M6SGDPB4Z94P11 01/09/2025 FR0010259150   1 200 116,94167 CCXE  
  IPSEN 549300M6SGDPB4Z94P11 01/09/2025 FR0010259150    200 116,90 TQEX  
  IPSEN 549300M6SGDPB4Z94P11 01/09/2025 FR0010259150   2 606 117,18388 XPAR  
  IPSEN 549300M6SGDPB4Z94P11 02/09/2025 FR0010259150    300 116,20 AQEU  
  IPSEN 549300M6SGDPB4Z94P11 02/09/2025 FR0010259150    500 116,20 CCXE  
  IPSEN 549300M6SGDPB4Z94P11 02/09/2025 FR0010259150    200 116,286 TQEX  
  IPSEN 549300M6SGDPB4Z94P11 02/09/2025 FR0010259150   3 600 116,41622 XPAR  
  IPSEN 549300M6SGDPB4Z94P11 03/09/2025 FR0010259150    300 116,70 AQEU  
  IPSEN 549300M6SGDPB4Z94P11 03/09/2025 FR0010259150    600 116,68333 CCXE  
  IPSEN 549300M6SGDPB4Z94P11 03/09/2025 FR0010259150    300 116,50967 TQEX  
  IPSEN 549300M6SGDPB4Z94P11 03/09/2025 FR0010259150   3 400 116,95335 XPAR  
  IPSEN 549300M6SGDPB4Z94P11 04/09/2025 FR0010259150   1 200 120,00 CCXE  
  IPSEN 549300M6SGDPB4Z94P11 04/09/2025 FR0010259150   3 400 119,88147 XPAR  
  IPSEN 549300M6SGDPB4Z94P11 05/09/2025 FR0010259150    300 120,00 € AQEU  
  IPSEN 549300M6SGDPB4Z94P11 05/09/2025 FR0010259150    600 120,05 CCXE  
  IPSEN 549300M6SGDPB4Z94P11 05/09/2025 FR0010259150    300 120,00 TQEX  
  IPSEN 549300M6SGDPB4Z94P11 05/09/2025 FR0010259150   3 400 119,80815 XPAR  
            23 038 118,01642    
                 
  • EN_IPSEN – Buy-back programme – Art 5 of MAR – Week 36_2025 (1)
Intas & Accord signs Agreement to acquire Prothya Biosolutions
Frost & Sullivan Recognizes TP with the 2026 Transformational Innovation Leadership Award for Redefining AI Operations and Governance in the Global BPO AI Industry
MWC 2026: SoundHound AI Launches Sales Assist Agent, Bringing Real-Time Agentic AI to the Retail Sales Floor
IOC and Samsung celebrate Solve for Tomorrow, Sport & Tech winners in Milan
Markel promotes Ben House to Director of Energy & Power
TAGGED:2025Adventureartbuy-backFR0010259150ipsenmar”newsParis:IPNPressReleaseprogrammeRegulated_Infoweek
Share This Article
Facebook Email Print
- Advertisement -

Follow US

Find US on Social Medias
FacebookLike
XFollow
YoutubeSubscribe

Weekly Newsletter

Subscribe to our newsletter to get our newest articles instantly!
Popular News
Vystar Enters Final Testing of Breakthrough Dialysis Water Filtration Technology
Health

Vystar Enters Final Testing of Breakthrough Dialysis Water Filtration Technology

GlobeNews Wire
GlobeNews Wire
29/01/2026
Standard Chartered and Dun & Bradstreet release latest Women Entrepreneurship Optimism Index
Schwarzkopf Professional Debuts ‘Hair by Schwarzkopf Pro’ with the Unveiling of this Year’s Defining Hair Colour Trend: Lived-in
Regeneron Provides Update on Phase 3 Trial of Fianlimab (LAG-3 Inhibitor) Combination in First-Line Unresectable or Metastatic Melanoma
Beebole launches a fully rebuilt platform after 18 years of independent, founder-led growth
- Advertisement -
- Advertisement -
- Advertisement -

Categories

  • Automobile
  • Entertainment
  • E-Sports
  • Food
  • Health
  • Technology
  • LifeStyle
  • Travel

About Us

Through our news networks, we raise millions of users' awareness. We are among the world's most reputable news networks.
Quick Link
Top Categories
  • Entertainment

Subscribe US

Subscribe to our newsletter to get our newest articles instantly!

AdkhabarAdkhabar
Copyright © 2021 - 2025 AdKhabar. All Rights Reserved. POWERED BY Life Care News.
Join Us!
Subscribe to our newsletter and never miss our latest news, podcasts etc..
Zero spam, Unsubscribe at any time.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?